Literature DB >> 35746934

The Future Is Noninvasive: A Brief Review of the Evolution and Clinical Utility of Vagus Nerve Stimulation.

Bashar W Badran1, Christopher W Austelle1.   

Abstract

Vagus nerve stimulation (VNS) is a form of neuromodulation that stimulates the vagus nerve. VNS had been suggested as an intervention in the late 1800s and was rediscovered in the late 1980s as a promising treatment for refractory epilepsy. Since then, VNS has been approved by the U.S. Food and Drug Administration (FDA) for treatment of epilepsy, morbid obesity, and treatment-resistant depression. Unfortunately, VNS is underutilized, as it is costly to implant and often only suggested when all other treatment options have been exhausted. Discovery of a noninvasive method of VNS known as transcutaneous auricular VNS (taVNS), which activates the vagus through stimulation of the auricular branch of the vagus nerve, has reignited excitement around VNS. taVNS has immense potential as a safe, at-home, wearable treatment for various neuropsychiatric disorders. Major strides are being made in both invasive and noninvasive VNS that aim to make this technology more accessible to patients who would find benefit, including the ongoing RECOVER trial, a randomized controlled trial in up to 1,000 individuals to further evaluate the efficacy of VNS for treatment-resistant depression. In this brief review, we first discuss the early history of VNS; then its clinical utility in FDA-approved indications; and, finally, noninvasive VNS.
Copyright © 2022 by the American Psychiatric Association.

Entities:  

Keywords:  Brain stimulation; Depression; Noninvasive VNS; Transcutaneous auricular VNS (taVNS); Vagus nerve stimulation (VNS); taVNS

Year:  2022        PMID: 35746934      PMCID: PMC9063597          DOI: 10.1176/appi.focus.20210023

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  46 in total

1.  Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures.

Authors:  C M DeGiorgio; S C Schachter; A Handforth; M Salinsky; J Thompson; B Uthman; R Reed; S Collins; E Tecoma; G L Morris; B Vaughn; D K Naritoku; T Henry; D Labar; R Gilmartin; D Labiner; I Osorio; R Ristanovic; J Jones; J Murphy; G Ney; J Wheless; P Lewis; C Heck
Journal:  Epilepsia       Date:  2000-09       Impact factor: 5.864

2.  Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.

Authors:  A John Rush; Harold A Sackeim; Lauren B Marangell; Mark S George; Stephen K Brannan; Sonia M Davis; Phil Lavori; Robert Howland; Mitchel A Kling; Barry Rittberg; Linda Carpenter; Philip Ninan; Francisco Moreno; Thomas Schwartz; Charles Conway; Michael Burke; John J Barry
Journal:  Biol Psychiatry       Date:  2005-09-01       Impact factor: 13.382

3.  Transcutaneous vagus nerve stimulation for partial onset seizure therapy. A new concept.

Authors:  E C Ventureyra
Journal:  Childs Nerv Syst       Date:  2000-02       Impact factor: 1.475

4.  Effects of Vagal Nerve Stimulation on Cognition and Quality of Life in Epilepsy.

Authors:  Carl B. Dodrill; George L. Morris
Journal:  Epilepsy Behav       Date:  2001-02       Impact factor: 2.937

5.  Transcutaneous Vagus Nerve Stimulation in Humans Induces Pupil Dilation and Attenuates Alpha Oscillations.

Authors:  Omer Sharon; Firas Fahoum; Yuval Nir
Journal:  J Neurosci       Date:  2020-11-19       Impact factor: 6.167

6.  Auricular transcutaneous electrical nerve stimulation in depressed patients: a randomized controlled pilot study.

Authors:  Ernst Hein; Magdalena Nowak; Olga Kiess; Teresa Biermann; Kristina Bayerlein; Johannes Kornhuber; Thomas Kraus
Journal:  J Neural Transm (Vienna)       Date:  2012-11-02       Impact factor: 3.575

7.  Tragus or cymba conchae? Investigating the anatomical foundation of transcutaneous auricular vagus nerve stimulation (taVNS).

Authors:  Bashar W Badran; Joshua C Brown; Logan T Dowdle; Oliver J Mithoefer; Nicholas T LaBate; James Coatsworth; William H DeVries; Christopher W Austelle; Lisa M McTeague; Alfred Yu; Marom Bikson; Dorothea D Jenkins; Mark S George
Journal:  Brain Stimul       Date:  2018-06-06       Impact factor: 8.955

8.  Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial.

Authors:  A Handforth; C M DeGiorgio; S C Schachter; B M Uthman; D K Naritoku; E S Tecoma; T R Henry; S D Collins; B V Vaughn; R C Gilmartin; D R Labar; G L Morris; M C Salinsky; I Osorio; R K Ristanovic; D M Labiner; J C Jones; J V Murphy; G C Ney; J W Wheless
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

9.  Transcutaneous vagus nerve stimulation: retrospective assessment of cardiac safety in a pilot study.

Authors:  Peter M Kreuzer; Michael Landgrebe; Oliver Husser; Markus Resch; Martin Schecklmann; Florian Geisreiter; Timm B Poeppl; Sarah Julia Prasser; Goeran Hajak; Berthold Langguth
Journal:  Front Psychiatry       Date:  2012-08-07       Impact factor: 4.157

Review 10.  Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders.

Authors:  James Douglas Bremner; Nil Z Gurel; Matthew T Wittbrodt; Mobashir H Shandhi; Mark H Rapaport; Jonathon A Nye; Bradley D Pearce; Viola Vaccarino; Amit J Shah; Jeanie Park; Marom Bikson; Omer T Inan
Journal:  J Pers Med       Date:  2020-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.